Showing 3811-3820 of 9968 results for "".
Vitiligo Update: Pathogenesis, Therapies, and Integrative Approaches
https://practicaldermatology.com/issues/may-june-2025/vitiligo-update-pathogenesis-therapies-and-integrative-approaches/35920/Vitiligo is a chronic autoimmune condition characterized by depigmented white patches due to melanocyte destruction, attributed to genetic factors and environmental triggers.Journal Club: New Research in Atopic Dermatitis
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-new-research-in-atopic-dermatitis/26560/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, chats with dermatologist Larry Eichenfield, MD, a member of the Practical Dermatology Editorial Board, about new research in atopic dermatitis (AD), as well as practical considerations and new treatments for the condition.Meeting the Needs of Today's Injectables Market
https://practicaldermatology.com/series/c-suite-chats/meeting-needs-todays-injectables-market/26926/David Moatazedi, president and CEO of Evolus, talks about trends in the injectables market and the needs of younger generations.Hoya ConBio - Medlite Demo
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/hoya-conbio-medlite-demo/19460/Quick demo on the benefits on using Medlite and how it can improve your practice.The Biosimilar Revolution: A Look at the Potential Impact
https://practicaldermatology.com/issues/april-2025/the-biosimilar-revolution-a-look-at-the-potential-impact/35596/With many biosimilars expected to gain regulatory approval in coming months and years, Practical Dermatology interviewed Collin Blattner, DO, FAAD—an editorial board member and double-board–certified dermatologist who owns Clearchoice Dermatology, which has 12 locations in Oregon and Washington—abouDrs. Rosen and Bhatia Highlight Latest Drugs at Maui Derm
https://practicaldermatology.com/programs/practical-dermatology/drs-rosen-and-bhatia-highlight-latest-drugs-at-maui-derm/32914/The current landscape of therapeutics for dermatologic conditions is dramatic, with new groundbreaking drugs continuously becoming available.Neuromodulators and Dermal Fillers: Dr. Gold
https://practicaldermatology.com/programs/practical-dermatology/neuromodulators-and-dermal-fillers-dr-gold/32694/Michael Gold, MD, talks about the new neurotoxins and applications, as well as fillers, that he covered during "Neuromodulators and Dermal Fillers: What's New, What's Coming and What Are We Doing That's New in 2025" at Maui Derm 2025.Clinical Development of Emrosi for Rosacea
https://practicaldermatology.com/series/c-suite-chats/clinical-development-emrosi-rosacea/32379/Claude Maraoui, President and CEO of Journey Medical, discusses the clinical development program for Emrosi, which was recently approved by the FDA for inflammatory lesions of rosacea in adults.Improving Treatment Capabilities for Vitiligo
https://practicaldermatology.com/series/c-suite-chats/improving-treatment-capabilities-for-vitiligo/29745/David Domzalski, CEO and President of Vyne Therapeutics, discusses what makes vitiligo difficult to treat and how his company is working to address those challenges.Cosmetic Benefits and Post-Treatment
https://practicaldermatology.com/series/pdt-in-practice/cosmetic-benefits-and-post-treatment/29117/Dr. Joel L. Cohen describes the cosmetic benefits of photodynamic therapy and the post-treatment considerations involved.